NEWS-SaiAo Biotech | CAR-T Cell Therapy & Biopharmaceutical

EN

EN
عربي

Home / NEWS

Patient Success Stories

Literature Downloads

a2ce77f8-f80e-404e-98e3-815845849111

01 October 2024

BCMA/GPRC5D bispecific CAR T-cell therapy for relapsed/refractory multiple myeloma with extramedullary disease: a single-center, single-arm, phase 1 trial

BCMA/GPRC5D bispecific CAR T-cell therapy for relapsed/refractory multiple myeloma with extramedullary disease: a single-center, single-arm, phase 1 trial

06 June 2025

Phase I trial validating a simplified autologous CD7 CAR-T manufacturing process without T-cell pre-selection, expanding accessibility for pediatric r/r T-ALL patients

Phase I trial validating a simplified autologous CD7 CAR-T manufacturing process without T-cell pre-selection, expanding accessibility for pediatric r/r T-ALL patients

View More >>
03 January 2025

Prominent Efficacy and Good Safety of Sequential CD19 and CD22 CAR-T Therapy in Relapsed/Refractory Adult B-cell Acute Lymphoblastic Leukemia

Exp Hematol Oncol 2025: Phase 2 study showing sequential CD19/CD22 CAR-T therapy delivers high complete remission rates with manageable toxicity in adult r/r B-ALL, with most responders achieving MRD-negative status.

View More >>
24 September 2025

Sequential CD19 and CD22 Chimeric Antigen Receptor T-cell Therapy for Childhood Refractory or Relapsed B-cell Acute Lymphocytic Leukaemia

Sequential CD19 and CD22 Chimeric Antigen Receptor T-cell Therapy for Childhood Refractory or Relapsed B-cell Acute Lymphocytic Leukaemia

View More >>
01 January 2026

Sequential CD7 CAR T-Cell Therapy and Allogeneic HSCT without GVHD Prophylaxis

N Engl J Med 2024: Landmark N Engl J Med study showing that CD7 CAR-T bridging to allogeneic HSCT without GVHD prophylaxis is feasible and effective for T-ALL patients, opening a new curative pathway.

View More >>
25 April 2023

Allogenic and Autologous Anti-CD7 CAR-T-cell Therapies in Relapsed or Refractory T-cell Malignancies

Allogenic and Autologous Anti-CD7 CAR-T-cell Therapies in Relapsed or Refractory T-cell Malignancies.

View More >>

1 2 3 4 5